Chiesi Nears EU Pediatric Approval for Lomitapide in Rare Cholesterol Disorder
Event summary
- CHMP issued positive opinion for lomitapide capsules in pediatric HoFH patients aged 5+
- European Commission decision expected by June 1, 2026
- Phase 3 study showed 53.5% mean reduction in LDL-C at week 24
- Lomitapide already approved for adult HoFH patients in EU since 2013
- HoFH affects 1 in 250,000 to 1 in 360,000 individuals worldwide
The big picture
Chiesi's potential expansion into pediatric HoFH treatment comes as rare disease therapies gain increasing attention from regulators and investors. The positive CHMP opinion positions Chiesi to capture a niche market with limited treatment options, particularly for ultra-rare genetic disorders. The company's focus on underserved patient communities aligns with broader industry trends toward personalized medicine and early intervention in genetic diseases.
What we're watching
- Regulatory Timing
- Whether the European Commission will meet the June 1, 2026 deadline for final approval
- Market Expansion
- How Chiesi will leverage this approval to expand lomitapide's reach in pediatric HoFH treatment globally
- Competitive Positioning
- The pace at which Chiesi can differentiate lomitapide from emerging gene therapies for HoFH
Related topics